MSLN and neoplasm: Preclinically, the STING agonist cGAMP both directly activates NK cells and sensitizes PDAC cells (e.g., ULBP2/5/6 upregulation and apoptosis), and, in combination with mesothelin-targeted CAR-NK-92, achieves superior tumor control and prolongs survival in mouse models [45].